Novartis has entered into an agreement and plan of merger with The Medicines Company to acquire the US-based biopharmaceutical company for $85 per share in cash, valuing the company at approximately $9.7 billion on a fully diluted equity basis. The offer price represents a premium of approximately 41% over The Medicines Company’s 30-day (to [...]